

**Welt – Lymphom – Tag  
Seminar für Patienten und Angehörige  
15. September 2007  
Wien**

Ein Vortrag von  
Univ. Prof. Dr. Johannes Drach



Medizinische Universität Wien  
Univ. Klinik für Innere Medizin I  
Klinische Abteilung für Onkologie



**AKTUELLE ASPEKTE IN DER THERAPIE  
DES MANTELZELL-LYMPHOMS**


Univ. Prof. Dr. Johannes Drach



Medizinische Universität Wien  
Univ. Klinik für Innere Medizin I  
Klinische Abteilung für Onkologie




# Non-Hodgkin's lymphomas



## Mantelzell-Lymphom (MCL)

- Häufiger im höheren Lebensalter (mittleres Alter bei Diagnosestellung 65 Jahre)
- Ursache der Erkrankung ist unbekannt
- Neben den Lymphknoten häufiger Befall anderer Organe
  - Magen-Darmtrakt
  - Knochenmark
  - Daher meist im fortgeschrittenen Stadium




## CHOP vs. R-CHOP Erstlinientherapie beim MCL

	CHOP	R-CHOP
Zahl der Patienten	62	64
<b>CR:</b>	<b>8%</b>	<b>32%</b>
<b>PR:</b>	<b>68%</b>	<b>61%</b>
<b>PR+CR:</b>	<b>76%</b>	<b>93%</b>


**p=0.001** (CR), **p=0.015** (PR+CR)

# Progressionsfreie Zeit CHOP versus R-CHOP



Lenz, et al. *J Clin Oncol*. 2005;23:1984.

# PFS After High-Dose Radiochemotherapy Followed by ASCT and Interferon- $\alpha$ (IFN- $\alpha$ ) Maintenance in MCL



Dreyling, et al. *Blood*. 2005;105:2677.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Roswitha Forstpointner, Martin Dreyling, Roland Repp, Sandra Hermann, Annette Hänel, Bernd Metzner, Christiane Pott, Frank Hartmann, Frank Rothmann, Robert Rohrbach, Hans-Peter Böck, Hannes Wandt, Michael Unterhalt, and Wolfgang Hiddemann

**147 patients relapsed/refractory**

**72 (49%) FL, 52(35%)MCL, 16 (11%) LPL**


**FCM X4 vs. R-FCM**

<u>Treatment</u>	<u>RR</u>	<u>CR</u>		<u>RR (For MCL)</u>
<b>R-FCM</b>	<b>79%</b>	<b>33%</b>	<b>P=0.01</b>	<b>58%</b>
<b>FCM</b>	<b>58%</b>	<b>46%</b>		<b>46%</b>

**Overall survival after start of therapy for patients with follicular lymphomas and mantle cell lymphomas randomized for FCM or R-FCM**

•FL (estimated)  $P=0.09$


ML  $P=0.0042$



# TARGETING LYMPHOMA CELLS AND THE MICROENVIRONMENT

Targeting tumor cells

CD20 Ab – Rituximab  
Chemotherapy



Targeting tumor cells  
and  
stromal cells

Bortezomib  
Immunomodulatory drugs

1. Rituximab + thalidomide (relapsed MCL)
2. R-CHOP + thalidomide (untreated MCL)
3. BORID (bortezomib + rituximab + dexamethasone) in heavily pretreated MCL